Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human umbilical cord mesenchymal stem cells + allogeneic islet
- Development stage
- Unknown
- Lead developer
- Shanghai ChangZheng Hospital
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
human umbilical cord mesenchymal stem cells + allogeneic islet is a combination cell therapy being investigated by Shanghai Changzheng Hospital for the treatment of various forms of diabetes, including type 1, type 2, and pancreatogenic diabetes associated with islet failure. The therapy involves the co-transplantation of allogeneic pancreatic islets, which provide a source of insulin-producing beta cells, and allogeneic human umbilical cord mesenchymal stem cells (hUCMSCs). The hUCMSCs are utilized for their potent immunomodulatory and anti-inflammatory properties, which help to mitigate the host immune response against the transplanted islets, reduce inflammation at the graft site, and potentially promote revascularization. This synergistic approach aims to improve the survival, engraftment, and long-term function of the transplanted islets, thereby restoring endogenous insulin production and improving glycemic control in patients. The combination is typically administered via portal vein infusion.
- Other names
- hUCMSCs Combined with Islet Transplantation
Beyond the preview
Go deeper on human umbilical cord mesenchymal stem cells + allogeneic islet.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human umbilical cord mesenchymal stem cells + allogeneic islet.